Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129246 · ClinicalTrials.gov registry record · Phase 1
Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00129246 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 40 participants.
The verdict
NCT00129246, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
Interventions
- DRUG Bupropion
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129246
The ClinicalTrials.gov registry entry for NCT00129246 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupropion is the first listed.
NCT00129246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129246 about?
NCT00129246 is a clinical study titled "Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain". This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
What is the current status of trial NCT00129246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00129246?
The interventions under investigation include: Bupropion (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00129246?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.